Next-Generation Insights: Integrating Genomics & Epigenomics in Oncology Clinical Trials

• Epigenomics: The new frontier for biomarker discovery
• Expand patient eligibility through combining genomic and epigenomic alterations
• Methylation-enhanced liquid biopsy improves deletion calling

Speakers:

BARRY OCONNOR

Head Senior Director, Biopharma Business Development Amea

Guardant Health